Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Kozono

Showing results (71-80 of 72) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 72 results.
JAMA|June 1, 2026
Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical TrialJamie E Chaft, Zhuoxin Sun, Charles M Rudin, et al.
Nature|December 19, 2018
Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockadeJeffrey J Ishizuka, Robert T Manguso, Collins K Cheruiyot, et al.
Pageof 8

Showing results (71-80 of 72) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 72 results.
JAMA|June 1, 2026
Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical TrialJamie E Chaft, Zhuoxin Sun, Charles M Rudin, et al.
Nature|December 19, 2018
Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockadeJeffrey J Ishizuka, Robert T Manguso, Collins K Cheruiyot, et al.
Pageof 8